- Home
- GYRO vs ALLK Comparison
GYRO vs ALLK Comparison
Compare GYRO & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRO
- ALLK
- Stock Information
- Founded
- GYRO 1946
- ALLK 2012
- Country
- GYRO United States
- ALLK United States
- Employees
- GYRO N/A
- ALLK N/A
- Industry
- GYRO Building operators
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- GYRO Real Estate
- ALLK Health Care
- Exchange
- GYRO Nasdaq
- ALLK Nasdaq
- Market Cap
- GYRO 19.3M
- ALLK 23.0M
- IPO Year
- GYRO N/A
- ALLK 2018
- Fundamental
- Price
- GYRO $7.93
- ALLK $0.33
- Analyst Decision
- GYRO
- ALLK Hold
- Analyst Count
- GYRO 0
- ALLK 3
- Target Price
- GYRO N/A
- ALLK $2.00
- AVG Volume (30 Days)
- GYRO 932.0
- ALLK 2.2M
- Earning Date
- GYRO 01-01-0001
- ALLK 05-08-2025
- Dividend Yield
- GYRO N/A
- ALLK N/A
- EPS Growth
- GYRO N/A
- ALLK N/A
- EPS
- GYRO N/A
- ALLK N/A
- Revenue
- GYRO $2,738,019.00
- ALLK N/A
- Revenue This Year
- GYRO N/A
- ALLK N/A
- Revenue Next Year
- GYRO N/A
- ALLK N/A
- P/E Ratio
- GYRO N/A
- ALLK N/A
- Revenue Growth
- GYRO N/A
- ALLK N/A
- 52 Week Low
- GYRO $6.80
- ALLK $0.22
- 52 Week High
- GYRO $11.96
- ALLK $1.56
- Technical
- Relative Strength Index (RSI)
- GYRO 39.32
- ALLK 60.40
- Support Level
- GYRO $6.80
- ALLK $0.31
- Resistance Level
- GYRO $8.39
- ALLK $0.33
- Average True Range (ATR)
- GYRO 0.17
- ALLK 0.00
- MACD
- GYRO 0.04
- ALLK 0.00
- Stochastic Oscillator
- GYRO 64.94
- ALLK 78.50
About GYRO Gyrodyne LLC
Gyrodyne LLC is a United States-based limited liability company. It operates in the ownership and management of industrial and medical office buildings segment. The company leases and manages various commercial properties such as medical offices and industrial properties. The properties owned by the company include Cortlandt Manor and Flowerfield.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.